Chronic Bronchitis

3 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Chronic Bronchitis has 3 FDA-approved novel treatments, led by Boehringer Ingelheim across 16 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Chronic Bronchitis Market Leaders

Companies with the most FDA-approved novel Chronic Bronchitis drugs.

Phase 3 Readouts Pro

8 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q4 2026

Pirfenidone Capsules （400 mg）

Beijing Continent Pharmaceutical Co, Ltd.

Estimated · fresh NCT07388680

Q4 2026

Meropenem and Pralurbactam

Qilu Pharmaceutical Co., Ltd.

Estimated · aging NCT07089186

Q4 2027

BV100 (300 mg)

BioVersys SAS

Estimated · fresh NCT07326540

Unlock 5 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Chronic Bronchitis Treatments by Mechanism

Top 5 mechanisms across 8 industry trials with a known mechanism of action.

See full pipeline →

Tetracycline-class Antibacterial

3 trials 2 sponsors

Fluoroquinolone Antibacterial

2 trials 2 sponsors

Interleukin-1 Receptor Antagonist

1 trials 1 sponsor

beta Lactamase Inhibitor

1 trials 1 sponsor

Interleukin-6 Antagonist

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Chronic Bronchitis Clinical Pipeline by Phase

230 industry-sponsored trials across 125 sponsors

Showing 22 of 22 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Laboratorio Farmaceutico SIT srl	BUCCALIN®	—	RECRUITING	2027-04	NCT06736288
SamA Pharmaceutical Co., Ltd	Atock Dry Syrup with placebo patch	—	RECRUITING	2027-07	NCT06411925
Dr. Md. Alimur Reza	Faropenem	—	RECRUITING	2025-09-30	NCT06804096
Pfizer	Zavicefta, Ceftazidime-Avibactam	—	COMPLETED	2023-08-31	NCT04882085
Pfizer	Zavicefta, Ceftazidime-Avibactam	—	COMPLETED	2023-05-04	NCT04774094
Beijing Minhai Biotechnology Co., Ltd	PCV13	—	COMPLETED	2022-11-13	NCT06210737
China National Biotec Group Company Limited	COVAX+IIV4; COVAX+PPV23	—	COMPLETED	2021-09-05	NCT04790851
China National Biotec Group Company Limited	IIV4 and PPV23	—	COMPLETED	2020-11-26	NCT04559204
Bactiguard AB	—	—	COMPLETED	2020-05-08	NCT04242706
TaiGen Biotechnology Co., Ltd.	Nemonoxacin	—	COMPLETED	2020-03-23	NCT05133752
Yuria-Pharm	Rheosorbilact®	—	COMPLETED	2020-02-17	NCT03824457
Ahn-Gook Pharmaceuticals Co.,Ltd	Synatura® 15 mL	—	COMPLETED	2018-05-02	NCT03623282
Pfizer	13-valent Pneumococcal conjugate vaccine	—	COMPLETED	2015-07	NCT02034877
bene-Arzneimittel GmbH	Tacholiquine	—	COMPLETED	2015-01	NCT02515799
Forest Laboratories	Ceftaroline fosamil	—	COMPLETED	2014-05	NCT01669980
Pfizer	VACCINE: 13-valent pneumococcal conjugate vaccine	—	COMPLETED	2013-10	NCT00744263
Halyard Health	Opioid based analgesia	—	COMPLETED	2012-09	NCT00673712
Johnson & Johnson	doripenem	—	COMPLETED	2011-09-05	NCT00986102
Bayer	Avelox (Moxifloxacin, BAY12-8039)	—	COMPLETED	2010-12	NCT00656747
Janssen-Cilag Ltd.,Thailand	Doripenem	—	COMPLETED	2010-07	NCT00965848
Sanofi	PRISTINAMYCIN XRP7263	—	TERMINATED	2023-02-20	NCT02332577
Forest Laboratories	Ceftaroline fosamil	—	WITHDRAWN	2013-09	NCT01666743

Showing 98 of 98 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Qilu Pharmaceutical Co., Ltd.	Meropenem and Pralurbactam	—	RECRUITING	2026-12	NCT07089186
Beijing Continent Pharmaceutical Co, Ltd.	Pirfenidone Capsules （400 mg）	—	RECRUITING	2026-12-30	NCT07388680
BioVersys SAS	BV100 (300 mg)	—	RECRUITING	2027-12-30	NCT07326540
Qilu Pharmaceutical Co., Ltd.	Meropenem and Pralurbactam	—	RECRUITING	2028-06	NCT07327619
Biotest	Trimodulin	—	RECRUITING	2028-07-31	NCT05722938
Ansun Biopharma, Inc.	DAS181	—	RECRUITING	2028-09-01	NCT03808922
Materia Medica Holding	Raphamin	—	RECRUITING	2028-12-31	NCT07650227
Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica	TAD® 600 mg/4 mL powder and solvent for solution for injection	—	RECRUITING	2025-06	NCT06296212
Zai Lab (Hong Kong), Ltd.	Omadacycline	—	RECRUITING	2025-01-01	NCT06162286
Fosun Adgenvax Biopharmaceutical Co.,Ltd.	13-valent pneumococcal conjugate vaccine (multivalent conjugate)	—	ACTIVE NOT RECRUITING	2025-06-30	NCT05759520
Nanjing Yoko Biomedical Co., Ltd.	YK-1169	—	NOT YET RECRUITING	2028-04-01	NCT07634198
Ahn-Gook Pharmaceuticals Co.,Ltd	AG2001	—	NOT YET RECRUITING	2026-03-31	NCT07198347
Yuhan Corporation	YHP2401	—	COMPLETED	2026-01-15	NCT07111468
AstraZeneca	Nirsevimab	—	COMPLETED	2025-11-24	NCT05110261
Meiji Seika Pharma Co., Ltd.	co-administration of cefepime and nacubactam	—	COMPLETED	2025-09-01	NCT05905055
Daewon Pharmaceutical Co., Ltd.	DW5121	—	COMPLETED	2025-05-27	NCT07093697
Materia Medica Holding	Raphamin	—	COMPLETED	2025-03-19	NCT06263881
Evopoint Biosciences Inc.	Combination of Imipenem/Cilastatin and XNW4107	—	COMPLETED	2024-09-29	NCT05204563
Paratek Pharmaceuticals Inc	Omadacycline	—	COMPLETED	2024-03-27	NCT04779242
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)	—	COMPLETED	2024-03-13	NCT06817187
Merck	V116	—	COMPLETED	2023-06-21	NCT05526716
Merck	V116	—	COMPLETED	2023-05-16	NCT05420961
Pfizer	ATM-AVI	—	COMPLETED	2023-02-23	NCT03329092
Aridis Pharmaceuticals, Inc.	AR-301	—	COMPLETED	2022-10-28	NCT03816956
Rigel Pharmaceuticals	Fostamatinib	—	COMPLETED	2022-09-05	NCT04629703
Merck	IMI/REL FDC	—	COMPLETED	2022-07-12	NCT03583333
Jiangsu Famous Medical Technology Co., Ltd.	Tanreqing capsule	—	COMPLETED	2022-06-02	NCT05305456
RAAS Nutritionals, LLC	Favipiravir	—	COMPLETED	2021-12-02	NCT05417997
Dompé Farmaceutici S.p.A	Reparixin	—	COMPLETED	2021-09-30	NCT04878055
Entasis Therapeutics	Sulbactam	—	COMPLETED	2021-07-26	NCT03894046
Hamad Medical Corporation	Anakinra	Interleukin-1 Receptor Antagonist [EPC]	COMPLETED	2021-03-01	NCT04643678
Biopharma Plasma LLC	IVIG	—	COMPLETED	2020-09-15	NCT04500067
Ahn-Gook Pharmaceuticals Co.,Ltd	AGS (Experimental)	—	COMPLETED	2020-07-29	NCT05344638
Merck	V114	—	COMPLETED	2020-04-03	NCT03950856
Basilea Pharmaceutica	ceftobiprole medocaril	—	COMPLETED	2020-03-16	NCT03439124
Merck	Imipenem	—	COMPLETED	2019-04-03	NCT02493764
Shionogi	Cefiderocol	—	COMPLETED	2019-04-01	NCT02714595
Shionogi	Cefiderocol	—	COMPLETED	2019-02-26	NCT03032380
Hyundai Pharm	Levotuss	—	COMPLETED	2018-10	NCT03489837
Hanlim Pharm. Co., Ltd.	HL301(Experimental)	—	COMPLETED	2018-09-21	NCT03654196
Melinta Therapeutics, Inc.	Delafloxacin	—	COMPLETED	2018-07-31	NCT02679573
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Tedizolid phosphate	—	COMPLETED	2018-06-22	NCT02019420
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	23-Valent Pneumococcal Polysaccharide Vaccine	—	COMPLETED	2018-06-07	NCT04278248
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Ceftolozane/tazobactam	—	COMPLETED	2018-05-15	NCT02070757
Nabriva Therapeutics AG	lefamulin	—	COMPLETED	2018-01	NCT02813694
R-Pharm	Nemonoxacin	—	COMPLETED	2017-12-13	NCT03551210
Walvax Biotechnology Co., Ltd.	7-valent pneumococcal conjugate vaccine	—	COMPLETED	2017-12-03	NCT02736240
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	Vabomere	beta Lactamase Inhibitor [EPC]	COMPLETED	2017-07-21	NCT02168946
TaiGen Biotechnology Co., Ltd.	Nemonoxacin	—	COMPLETED	2017-05-04	NCT02205112
Bayer	Amikacin Inhalation Solution (BAY41-6551)	—	COMPLETED	2017-04-07	NCT01799993
Nabriva Therapeutics AG	lefamulin	—	COMPLETED	2017-04	NCT02559310
Paratek Pharmaceuticals Inc	Omadacycline	—	COMPLETED	2017-02-05	NCT02531438
Achaogen, Inc.	plazomicin	—	COMPLETED	2016-08-18	NCT01970371
Inmunotek S.L.	Biological vaccine	—	COMPLETED	2016-05	NCT01734811
Pfizer	ceftazidim-avibactam (CAZ-AVI, experimental product)	—	COMPLETED	2016-01	NCT01808092
Hyundai Pharmaceutical Co., LTD.	Acebrophylline	—	COMPLETED	2016-01	NCT02792946
Melinta Therapeutics, Inc.	Solithromycin	—	COMPLETED	2015-07	NCT01968733
GSK	Synflorix™	—	COMPLETED	2015-06-29	NCT01746108
Bayer	Ciprofloxacin (Cipro, BAYQ3939)	—	COMPLETED	2015-03	NCT01561794
Melinta Therapeutics, Inc.	Solithromycin	—	COMPLETED	2014-10	NCT01756339
Forest Laboratories	Ceftaroline fosamil	—	COMPLETED	2014-04	NCT01530763
Korea United Pharm. Inc.	KALOMIN™ Tab.	—	COMPLETED	2013-12	NCT02151734
GSK	Synflorix (3-Dose)	—	COMPLETED	2013-07-15	NCT01641133
Pfizer	Ceftaroline	—	COMPLETED	2013-05	NCT01371838
TaiGen Biotechnology Co., Ltd.	Levofloxacin	Fluoroquinolone Antibacterial [EPC]	COMPLETED	2012-08	NCT01529476
GSK	Pneumococcal conjugate vaccine Synflorix (GSK1024850A)	—	COMPLETED	2012-01-31	NCT00839254
GSK	Pneumococcal conjugate vaccine GSK1024850A	—	COMPLETED	2012-01-31	NCT00861380
GSK	Synflorix™( GSK1024850A)	—	COMPLETED	2011-07-26	NCT01153841
Pfizer	ampicillin sodium/sulbactam sodium	—	COMPLETED	2011-04	NCT01189487
Ahn-Gook Pharmaceuticals Co.,Ltd	Theobromine 300mg	—	COMPLETED	2011-02	NCT01416480
Ahn-Gook Pharmaceuticals Co.,Ltd	AG NPP709syrup	—	COMPLETED	2010-05	NCT01151202
Pfizer	Azithromycin	—	COMPLETED	2010-03	NCT00809328
GSK	Pneumococcal conjugate vaccine GSK1024850A	—	COMPLETED	2009-11-13	NCT00814710
GSK	Pneumococcal conjugate vaccine GSK 1024850A	—	COMPLETED	2009-10-05	NCT00907777
Bayer	Avelox (Moxifloxacin, BAY12-8039)	—	COMPLETED	2009-05	NCT00717561
Forest Laboratories	Ceftaroline fosamil for Injection	—	COMPLETED	2008-12	NCT00621504
GSK	GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)	—	COMPLETED	2008-11-10	NCT00609492
GSK	GSK1024805A	—	COMPLETED	2008-06-02	NCT00624819
Biotest	Trimodulin	—	TERMINATED	2025-05-05	NCT05531149
Dompé Farmaceutici S.p.A	Reparixin	—	TERMINATED	2024-07-29	NCT05254990
Aridis Pharmaceuticals, Inc.	Suvratoxumab	—	TERMINATED	2024-07-08	NCT05331885
PTC Therapeutics	PTC299	—	TERMINATED	2022-07-20	NCT04439071
RECORDATI GROUP	Siltuximab	Interleukin-6 Antagonist [EPC]	TERMINATED	2021-04-01	NCT04616586
AstraZeneca	Ravulizumab	—	TERMINATED	2021-02-08	NCT04369469
Dompé Farmaceutici S.p.A	Reparixin	—	TERMINATED	2020-11-27	NCT04794803
Polyphor Ltd.	Murepavadin	—	TERMINATED	2019-07-17	NCT03409679
Polyphor Ltd.	Murepavadin	—	TERMINATED	2019-07-17	NCT03582007
Melinta Therapeutics, Inc.	Solithromycin	—	TERMINATED	2018-03-21	NCT02605122
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Ceftolozane/Tazobactam	—	TERMINATED	2013-11-20	NCT01853982
Abbott Nutrition	—	—	TERMINATED	2012-11	NCT01477723
Johnson & Johnson	Cefepime	—	TERMINATED	2012-03	NCT01110421
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Doripenem	—	TERMINATED	2011-06	NCT00589693
Venatorx Pharmaceuticals, Inc.	Cefepime-taniborbactam	—	WITHDRAWN	2027-06	NCT06168734
ImmunityBio, Inc.	Nogapendekin alfa inbakicept (NAI)	—	WITHDRAWN	2029-04-15	NCT07492875
Melinta Therapeutics, Inc.	Meropenem-Vaborbactam	—	WITHDRAWN	2020-06	NCT03006679
Durata Therapeutics Inc., an affiliate of Allergan plc	Dalbavancin	—	WITHDRAWN	2016-11	NCT02269644
Pfizer	Tigecycline	Tetracycline-class Antibacterial [EPC]	WITHDRAWN	2014-05	NCT01602874
Wyeth is now a wholly owned subsidiary of Pfizer	Tigecycline	Tetracycline-class Antibacterial [EPC]	WITHDRAWN	2014-05	NCT00914888

Showing 74 of 74 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Omnix Medical Ltd	OMN6	—	RECRUITING	2027-03	NCT06087536
Synairgen Research Ltd.	SNG001	—	RECRUITING	2027-04	NCT06999603
MiNK Therapeutics	agenT-797	—	RECRUITING	2027-06	NCT07615010
Vasomune Therapeutics, Inc.	AV-001 Injection	—	RECRUITING	2026-05	NCT05123755
Jiangsu HengRui Medicine Co., Ltd.	HRS-8427	—	RECRUITING	2026-02	NCT06841731
Shanghai SIMR Biotechnology Co., Ltd.	SR1375 capsule 3mg+regular treatments	—	RECRUITING	2025-10-15	NCT06577558
Mundipharma Research Limited	Co-Trimoxazole	—	RECRUITING	2025-05	NCT05835479
Eagle Pharmaceuticals, Inc.	CAL02	—	ACTIVE NOT RECRUITING	2026-02-10	NCT05776004
CanSino Biologics Inc.	24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M)	—	NOT YET RECRUITING	2026-11-24	NCT07600983
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQD3524	—	NOT YET RECRUITING	2027-07	NCT07512596
BioVersys AG	BV100 with 50 mg polymyxin B plus ceftazidime/avibactam	—	NOT YET RECRUITING	2028-03	NCT07431307
Aptarion Biotech AG	AON-D21	—	COMPLETED	2026-03-16	NCT05962606
Korea Arlico Pharm. Co., Ltd	ALC-2203-1	—	COMPLETED	2025-11-21	NCT07061925
GSK	AFX3772	—	COMPLETED	2025-09-18	NCT05412030
BioVersys AG	BV100 plus Polymyxin B	—	COMPLETED	2024-11-01	NCT05685615
Shionogi	Cefiderocol	—	COMPLETED	2024-09-17	NCT04215991
Enlivex Therapeutics Ltd.	Allocetra-OTS	—	COMPLETED	2024-01-12	NCT04612413
AstraZeneca	Tozorakimab	—	COMPLETED	2023-05-30	NCT04631016
Mirror Biologics, Inc.	AlloStim	—	COMPLETED	2023-03-01	NCT04441047
Shionogi	Cefiderocol	—	COMPLETED	2023-02-06	NCT04335539
LimmaTech Biologics AG	Kleb4V target dose	—	COMPLETED	2022-09-26	NCT04959344
MediciNova	Ibudilast	—	COMPLETED	2022-06-30	NCT04429555
Merck	V116	—	COMPLETED	2021-07-12	NCT04168190
CalciMedica, Inc.	Auxora (Part 1)	—	COMPLETED	2021-06-28	NCT04345614
Shaperon	NuSepin® 0.1 mg	—	COMPLETED	2021-04-13	NCT04565379
Kamada, Ltd.	Kamada Anti-SARS-CoV-2	—	COMPLETED	2020-11-26	NCT04550325
GSK	ASP3772	—	COMPLETED	2020-09-28	NCT03803202
Tigenix S.A.U.	Cx611	—	COMPLETED	2020-07-07	NCT03158727
Aridis Pharmaceuticals, Inc.	AR-105	—	COMPLETED	2019-04-25	NCT03027609
BioAegis Therapeutics Inc.	Recombinant Human Plasma Gelsolin	—	COMPLETED	2019-04-02	NCT03466073
MedImmune LLC	MEDI4893	—	COMPLETED	2018-10-02	NCT02296320
EmeraMed	Emeramide	—	COMPLETED	2018-05-30	NCT03123692
Biogen	Bardoxolone methyl	—	COMPLETED	2018-01-19	NCT02036970
Hanlim Pharm. Co., Ltd.	HL301	—	COMPLETED	2017-08-17	NCT03309800
Wockhardt	Nafithromycin 800 mg 3 days	—	COMPLETED	2017-07	NCT02903836
Merck	Prevnar 13®	—	COMPLETED	2016-07-01	NCT02037984
Aridis Pharmaceuticals, Inc.	KBSA301	—	COMPLETED	2016-05	NCT01589185
Genocea Biosciences, Inc.	GEN-004 with Aluminum Hydroxide Adjuvant	—	COMPLETED	2016-04	NCT02116998
Cardeas Pharma	Amikacin fosfomycin inhalation solution	—	COMPLETED	2016-03	NCT01969799
PharmaKing	N02RS1 1200mg	—	COMPLETED	2016-03	NCT02637310
Polyphor Ltd.	POL7080	—	COMPLETED	2015-12	NCT02096328
Biotest	BT086	—	COMPLETED	2015-02	NCT01420744
Hanlim Pharm. Co., Ltd.	HL301 300mg capsule	—	COMPLETED	2014-07	NCT02250027
TaiGen Biotechnology Co., Ltd.	Nemonoxacin 500 mg	—	COMPLETED	2013-12	NCT01944774
PharmaKing	Combination of Broussonetia spp and Lonicera spp	—	COMPLETED	2013-11	NCT01979926
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Faropenem（high dose group）	—	COMPLETED	2012-07	NCT01886053
Yuhan Corporation	YHD001 dose level 1	—	COMPLETED	2012-05	NCT01420445
Melinta Therapeutics, Inc.	Levofloxacin	Fluoroquinolone Antibacterial [EPC]	COMPLETED	2011-07	NCT01168713
AstraZeneca	AZD5069 50mg	—	COMPLETED	2011-03	NCT01233232
TaiGen Biotechnology Co., Ltd.	Nemonoxacin 3 tablets	—	COMPLETED	2010-08	NCT01537250
ADMA Biologics, Inc.	RI-001	—	COMPLETED	2010-05	NCT00632463
Valneva Austria GmbH	IC43	—	COMPLETED	2010-02	NCT00876252
Kenta Biotech Ltd	KBPA-101	—	COMPLETED	2009-07	NCT00851435
Pfizer	sulopenem and PF-03709270	—	COMPLETED	2009-06	NCT00797108
Mesoblast, Inc.	Prochymal™	—	COMPLETED	2009-03-09	NCT00683722
Humanigen, Inc.	KB001	—	COMPLETED	2009-03	NCT00691587
Senhwa Biosciences, Inc.	CX-4945 (SARS-CoV-2 domain)	—	TERMINATED	2025-04-22	NCT06202521
Bristol-Myers Squibb	CC-90001	—	TERMINATED	2021-12-24	NCT03142191
CalciMedica, Inc.	CM4620-IE (Injectable Emulsion)	—	TERMINATED	2021-12-21	NCT04661540
Celularity Incorporated	CYNK-001	—	TERMINATED	2021-08-30	NCT04365101
Ionis Pharmaceuticals, Inc.	ION-827359	—	TERMINATED	2021-04-27	NCT04441788
PhaseBio Pharmaceuticals Inc.	Pemziviptadil (PB1046)	—	TERMINATED	2020-12-02	NCT04433546
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.	UNIKINON (Chloroquine phosphate) 200mg tablets	—	TERMINATED	2020-11-30	NCT04344951
Eli Lilly	LY3127804	—	TERMINATED	2020-10-12	NCT04342897
Arsanis, Inc.	ASN100	—	TERMINATED	2018-07-19	NCT02940626
Thrombologic ApS	Ilomedin and Integrilin	—	TERMINATED	2014-03	NCT01532544
IASO Pharma Inc.	Zabofloxacin	—	TERMINATED	2012-04	NCT01081964
Furiex Pharmaceuticals, Inc	JNJ-32729463	—	TERMINATED	2011-10	NCT01198626
Pfizer	tigecycline	Tetracycline-class Antibacterial [EPC]	TERMINATED	2011-06	NCT00707239
Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Jaktinib hydrochloride tablets	—	WITHDRAWN	2024-04-23	NCT05702788
CalciMedica, Inc.	Auxora	—	WITHDRAWN	2022-07	NCT05171920
Beyond Air Inc.	—	—	WITHDRAWN	2020-11-15	NCT04456088
Cardeas Pharma	Amikacin Fosfomycin Inhalation Solution	—	WITHDRAWN	2015-12	NCT02218359
Boehringer Ingelheim	BIBW 2948 BS	—	WITHDRAWN	2008-09	NCT00726479

Showing 36 of 36 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Cho Pharma Inc.	Glyconjugate Klebsiella pneumoniae bivalent vaccine	—	RECRUITING	2026-11-05	NCT07016152
Pfizer	Ibuzatrelvir co-process API film coated tablet	—	RECRUITING	2026-06-03	NCT07552779
GSK	Pn-MAPS30plus	—	ACTIVE NOT RECRUITING	2026-12-09	NCT07428759
NextCell Pharma Ab	ProTrans®	—	ACTIVE NOT RECRUITING	2027-03-31	NCT04896853
Pfizer	PG4 vaccine in Buffer 1 with low dose PA-001	—	ACTIVE NOT RECRUITING	2027-10-21	NCT07086677
MicrobiotiX Co., Ltd	MP101	—	NOT YET RECRUITING	2026-12	NCT07492771
GSK	Pn-MAPS30plus	—	NOT YET RECRUITING	2027-02-22	NCT07406334
GSK	Pn-MAPS30plus	—	NOT YET RECRUITING	2028-04-03	NCT07406347
Op-T LLC	OPT101	—	NOT YET RECRUITING	2026-04	NCT06669403
GSK	Pn-MAPS30plus	—	COMPLETED	2026-05-06	NCT07105722
GPN Vaccines	Gamma PN3	—	COMPLETED	2025-03-31	NCT06562790
Merck	Ceftolozane/Tazobactam	—	COMPLETED	2024-09-14	NCT04223752
CanSino Biologics Inc.	PBPV	—	COMPLETED	2023-09-14	NCT05622942
Heronova Pharmaceuticals	Remdesivir	—	COMPLETED	2023-03-27	NCT06860282
Institute of Vaccines and Medical Biologicals, Vietnam	COVIVAC	—	COMPLETED	2021-06-06	NCT04830800
Paratek Pharmaceuticals Inc	Omadacycline	—	COMPLETED	2020-03-23	NCT04160260
LimmaTech Biologics AG	Bioconjugate pneumococcal vaccine	—	COMPLETED	2018-09-12	NCT03303976
Melinta Therapeutics, Inc.	Delafloxacin	—	COMPLETED	2018-07-19	NCT03534622
Combioxin SA	CAL02 Low-dose	—	COMPLETED	2018-02-20	NCT02583373
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Ceftolozane/Tazobactam - Multiple Doses	—	COMPLETED	2017-06-15	NCT02387372
Meiji Seika Pharma Co., Ltd.	ME1100 inhalation solution	—	COMPLETED	2017-03-22	NCT02459158
Tetraphase Pharmaceuticals, Inc	TP-271	—	COMPLETED	2016-09-28	NCT02724085
Dompé Farmaceutici S.p.A	SCMC-lys powder 1.35 g	—	COMPLETED	2016-07-25	NCT02858193
MedImmune LLC	MEDI3902 - Dose 1	—	COMPLETED	2015-04-20	NCT02255760
Genocea Biosciences, Inc.	GEN-004 Low Dose	—	COMPLETED	2015-02	NCT01995617
Sanofi	Pneumococcal Vaccine High Dose (Formulation 1)	—	COMPLETED	2013-03	NCT01446926
Sanofi	Pneumococcal vaccine Formulation 1	—	COMPLETED	2011-01	NCT01444352
Sanofi	Pneumococcal Vaccine Formulation 1	—	COMPLETED	2010-09	NCT01444339
Pfizer	CP-70,429 and PF-03709270	—	COMPLETED	2010-03	NCT00759564
GSK	GSK2231395A	—	COMPLETED	2009-05-04	NCT00814489
Clarametyx Biosciences, Inc.	CMTX-101	—	TERMINATED	2024-08-02	NCT05629741
Pfizer	Ceftazidime-avibactam	—	TERMINATED	2021-04-09	NCT04040621
Shionogi	Cefiderocol	—	TERMINATED	2019-10-08	NCT03862040
Basilea Pharmaceutica	Ceftobiprole	—	TERMINATED	2009-11	NCT00771719
GSK	GSK2231395A	—	TERMINATED	2009-04-07	NCT00849069
Merck	Frespaciguat	—	WITHDRAWN	2020-11-10	NCT04425733

Novel Chronic Bronchitis Drugs by Company (New molecular entities)

2 companies have an FDA-approved novel drug for Chronic Bronchitis.

Boehringer Ingelheim 2 drugs

STIOLTO RESPIMAT

OLODATEROL HYDROCHLORIDE

NDA 2015

STRIVERDI RESPIMAT

OLODATEROL HYDROCHLORIDE

GSK 1 drug

Reformulations (5 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.